Evofem Biosciences Inc

Company Profile

Evofem Biosciences Inc had its IPO on 2018-01-17 under the ticker symbol EVFM.

The company operates in the Healthcare sector and Biotechnology industry. Evofem Biosciences Inc has a staff strength of 119 employees.

Stock update

Shares of Evofem Biosciences Inc opened at $0.03 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $0.02 - $0.04, and closed at $0.02.

This is a -29.14% slip from the previous day's closing price.

A total volume of 17,174,669 shares were traded at the close of the day’s session.

In the last one week, shares of Evofem Biosciences Inc have increased by +65.33%.

Evofem Biosciences Inc's Key Ratios

Evofem Biosciences Inc has a market cap of $6.21 million, indicating a price to book ratio of 8.372 and a price to sales ratio of 0.42.

In the last 12-months Evofem Biosciences Inc’s revenue was $20.23 million with a gross profit of $4.19 million and an EBITDA of $-108440000. The EBITDA ratio measures Evofem Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evofem Biosciences Inc’s operating margin was -541.33% while its return on assets stood at -124.75% with a return of equity of -387.27%.

In Q4, Evofem Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 272.1%.

Evofem Biosciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-14.61 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evofem Biosciences Inc’s profitability.

Evofem Biosciences Inc stock is trading at a EV to sales ratio of 7.2023 and a EV to EBITDA ratio of -0.8469. Its price to sales ratio in the trailing 12-months stood at 0.42.

Evofem Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$42.28 million

Total Liabilities

$116.71 million

Operating Cash Flow

$0

Capital Expenditure

$136000

Dividend Payout Ratio

0%

Evofem Biosciences Inc ended 2023 with $42.28 million in total assets and $0 in total liabilities. Its intangible assets were valued at $42.28 million while shareholder equity stood at $-78044000.00.

Evofem Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $116.71 million in other current liabilities, 10000.00 in common stock, $-930358000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.75 million and cash and short-term investments were $7.75 million. The company’s total short-term debt was $80,127,000 while long-term debt stood at $0.

Evofem Biosciences Inc’s total current assets stands at $31.79 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $12.76 million compared to accounts payable of $14.54 million and inventory worth $5.18 million.

In 2023, Evofem Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $136000.

Comparatively, Evofem Biosciences Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.02

52-Week High

$5.7

52-Week Low

$0.013

Analyst Target Price

$1.8

Evofem Biosciences Inc stock is currently trading at $0.02 per share. It touched a 52-week high of $5.7 and a 52-week low of $5.7. Analysts tracking the stock have a 12-month average target price of $1.8.

Its 50-day moving average was $0.04 and 200-day moving average was $0.27 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.

Around 13.5% of the company’s stock are held by insiders while 446.4% are held by institutions.